Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 15c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.03, $0.15 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $43.45 million.

Sees combined net product sales from both HETLIOZ® and Fanapt® $180 to $200 million

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• Citi upgrades Bath & Body Works to Buy with $25 price target